The employed p53-negative lymphoid cell line model clearly has limitations [51, 52], but the multiple levels of agreement between cell line and tumor-derived mutation patterns encourage the further use of isogenic cell line models to decipher the complex mutational processes in human cancer. This evidence concerns the gene TP53 and cancer.